Application of medium-carbon olefine acid and derivative thereof in preparation of medicine for promoting revascularization and neurological function recovery
Patent Information
- Application Number
- CN202411053290.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
目前只有少数病人获益,且幸存者即使接受及时、综合的康复治疗,仍会遗留一定程度后遗症,包括肢体瘫痪、吞咽障碍或失语等,影响患者的日常生活质量,也给家庭和社会带来沉重的负担
[0020] Beneficial effects: The present invention discloses the application of medium-carbon alkenoic acid and its derivatives in the preparation of drugs that promote vascular regeneration and neurological function recovery. Medium-carbon alkenoic acid and its derivatives have the ability to promote endothelial cell proliferation, migration, blood vessel Small molecule compounds that regenerate, inhibit nerve cell apoptosis and promote nerve cell vitality: are cheap to synthesize, can accelerate the repair of damaged tissue, and have the potential to treat brain diseases.
Smart Images

Figure CN118976017A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and in particular to the application of a medium-carbon olefinic acid and its derivatives in the preparation of drugs for promoting angiogenesis and nerve function recovery. Background Art
[0002] Cerebral stroke, also known as cerebral infarction, includes ischemic stroke and hemorrhagic stroke. It is an acute cerebrovascular disease. It is a group of diseases with high morbidity, high mortality and high disability rate, which are caused by brain tissue damage due to blockage of cerebral blood vessels or sudden rupture of blood vessels, resulting in blood flow into the brain. Nearly 20 million people are affected every year, but the current treatment methods are very limited. The treatment of ischemic stroke usually takes measures such as vascular expansion, endarterectomy or arterial bypass surgery. The treatment of hemorrhagic stroke usually focuses on the removal of hemangiomas and thrombi. These treatment methods have strict time window restrictions, and blood circulation and oxygen supply to the ischemic area must be restored in time. At present, only a few patients benefit from it, and even if the survivors receive timely and comprehensive rehabilitation treatment, they will still have a certain degree of sequelae, including limb paralysis, swallowing disorders or aphasia, which affects the patient's daily quality of life and also brings a heavy burden to the family and society. Immediate treatment after the occurrence of stroke and restoration of blood supply to the lesion as soon as possible can significantly improve the prognosis. The brain microenvironment of ischemic stroke is generally characterized by inflammation and hypoxia, and the surrounding neurons will be irreversibly damaged. Therefore, the research on drugs for vascular regeneration to restore oxygen supply in stroke treatment is of great significance and has become a research hotspot. Very few drugs can be successfully marketed for clinical use. The development of drugs that can promote brain vascular regeneration and neurological function recovery after stroke is an urgent problem to be solved in the treatment of stroke sequelae.
[0003] Therefore, exploring and developing a new drug that has definite therapeutic effects on both ischemic and hemorrhagic stroke has important clinical value and practical significance. Summary of the invention
[0004] The technical problem to be solved by the present invention is to address the deficiencies of the prior art and to provide an application of a medium-carbon olefinic acid and its derivatives in the preparation of a drug for promoting angiogenesis and nerve function recovery. The medium-carbon olefinic acid and its derivatives are used to promote angiogenesis and effectively protect nerve cells from hypoxia and inflammatory damage, thereby improving the sequelae of ischemic and hemorrhagic stroke.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0006] Application of medium-carbon olefinic acid and its derivatives in the preparation of drugs for promoting angiogenesis and nerve function recovery.
[0007] Wherein, the medium-carbon olefinic acid includes cis-2-medium-carbon olefinic acid and trans-2-medium-carbon olefinic acid; the medium-carbon olefinic acid derivatives include cis-2-medium-carbon olefinic acid derivatives and trans-2-medium-carbon olefinic acid derivatives.
[0008] Wherein, the carbon chain length of the medium-chain olefinic acid and its derivatives is 6 to 16.
[0009] Preferably, the carbon chain length of the medium-chain olefinic acid and its derivatives is 6 to 12.
[0010] Preferably, the cis-2-meso-olefinic acid is cis-2-decenoic acid and / or cis-2-dodecenoic acid; the trans-2-meso-olefinic acid is any one or a combination of trans-2-hexadecenoic acid, trans-2-octadecenoic acid, trans-2-decenoic acid, and trans-2-dodecenoic acid; and the cis-2-meso-olefinic acid derivative is cis-11-methyl-2-dodecenoic acid.
[0011] Wherein, the cis-2-dodecenoic acid is a biologically active small molecule BDSF, which is a diffusible signal molecule that can serve as a medium for information exchange between cells. The specific structure is:
[0012]
[0013] Wherein, the cis-11-methyl-2-dodecenoic acid is a biologically active small molecule DSF, which is a derivative of BDSF, and the specific structure is:
[0014]
[0015] Wherein, the concentration of the medium-carbon olefinic acid and its derivatives is 5 to 100 μM.
[0016] Preferably, the concentration of the medium-chain olefinic acid and its derivatives is 10 to 60 μM.
[0017] Preferably, the concentration of the medium-chain olefinic acid and its derivatives is 20-40 μM.
[0018] In some embodiments of the present invention, by adding the above-mentioned medium-chain olefinic acids and their derivatives to a complete culture medium containing endothelial cells and co-incubating them, it is further found through cell proliferation experiments, scratch experiments, and angiogenesis experiments that the medium-chain olefinic acids can promote the proliferation, migration and angiogenesis of endothelial cells, promote the functional recovery of nerve cells, increase the vitality of nerve cells and inhibit their apoptosis.
[0019] The dosage form of the drug includes but is not limited to any one of tablets, capsules, powders, oral liquids, syrups, granules, pills, orodisintegrating tablets, sustained-release tablets, patches, micropellets, microcapsules, liposomes, microspheres, sustained-release preparations, and controlled-release preparations.
[0020] Beneficial effects: The present invention discloses the use of medium-carbon olefinic acids and their derivatives in the preparation of drugs for promoting angiogenesis and nerve function recovery. Medium-carbon olefinic acids and their derivatives are small molecule compounds that can promote endothelial cell proliferation, migration, angiogenesis, inhibit nerve cell apoptosis and promote nerve cell vitality. They are cheap to synthesize, can accelerate the repair of damaged tissues, and have the potential to treat brain diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The present invention will be more preferably described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0022] Figure 1 This is a graph showing the effect of different concentrations of BDSF on the viability of HUVEC cells in an embodiment of the present invention;
[0023] Figure 2 This is a graph showing the effect of BDSF on the proliferation rate of HUVEC in an embodiment of the present invention;
[0024] Figure 3 : is a diagram showing the effect of BDSF on HUVEC migration in the embodiment of the present invention; wherein A is an image of the Transwell of the chemotaxis experiment of HUVEC, B is a quantitative analysis of the Transwell results, C is a representative image of HUVEC migration at 0 hours, 12 hours and 24 hours, and D is a quantitative analysis of the cell scratch test;
[0025] Figure 4 The results of the in vitro angiogenesis test of HUVEC cells by BDSF in the examples of the present invention; wherein A is an image of HUVECs in vitro angiogenesis under different treatment conditions, B is a representative angiogenesis image of vascular paths (red), nodes (yellow) and vascular contours (green) within 3 hours and 6 hours, C is a quantitative analysis of the effect of BDSF on 3-hour angiogenesis (vascular area percentage, number of vascular nodes, total vascular length), and D is a quantitative analysis of the effect of BDSF on 6-hour angiogenesis (vascular area percentage, number of vascular nodes, total vascular length);
[0026] Figure 5 This is a graph showing the effects of DSF, BDSF, trans-C12, cis-C10, trans-C10, trans-C8 and trans-C6 on the proliferation rate of HUVEC cells (trans is trans, cis is cis);
[0027] Figure 6 The graph shows the effects of DSF, BDSF, trans-C12, cis-C10, trans-C10, trans-C8 and trans-C6 on the neuronal PC12 cells; A is the flow cytometry analysis of the apoptotic behavior of the cells and the quantification of the normal cell / apoptotic cell ratio; B is the CCK-8 detection of cell activity. DETAILED DESCRIPTION
[0028] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0029] Example 1: Effects of different concentrations of BDSF on cell viability
[0030] In this example, human umbilical vein endothelial cells (HUVEC) were selected as the research object, and the specific steps were as follows:
[0031] S1. Take HUVEC cells with good growth status, inoculate them into 96-well plates, add ECM complete medium, and each well contains 2×10 3 Cells were treated with BDSF at final concentrations of 5 μM, 10 μM, 20 μM, 40 μM, 60 μM and 80 μM, respectively, and a control group without BDSF was set up and incubated in a cell culture incubator at 37°C and 5% CO2 for 48 h;
[0032] S2. Add 10 μL of CCK-8 solution to each well containing HUVEC culture medium and incubate for another 2 h;
[0033] S3. Measure the absorbance of each well at 450 nm using a microplate reader.
[0034] Figure 1 The figure shows the survival rate of HUVEC cells after adding different concentrations of BDSF. It can be seen from the figure that when the final concentration of BDSF added is 20 μM, the growth rate of HUVEC cells is the highest, so 20 μM BDSF is preferred for the next step of research.
[0035] Example 2: Effect of BDSF on the proliferation of endothelial cells
[0036] In this example, HUVEC cells were selected as the proliferation research object, and the specific steps were as follows:
[0037] S1. Take HUVEC cells with good growth status, inoculate them into 96-well plates, add ECM complete medium, and each well contains 2×10 3The cells were treated with PBS (control group), BDSF with a final concentration of 20 μM, and vascular epidermal growth factor (VEGF) at 20 ng / mL, respectively, and incubated in a cell culture incubator at 37°C and 5% CO2 for 48 h.
[0038] S2. Add 10 μL of CCK-8 solution to each well containing HUVEC culture medium and incubate for another 2 h;
[0039] S3. Measure the absorbance of each well at 450 nm using a microplate reader.
[0040] Figure 2 The figure shows the effect of 20 μM BDSF and 20 ng / mL VEGF on the proliferation rate of HUVEC. It can be seen from the figure that the proliferation effect of BDSF and VEGF is equivalent, which is 59% and 98% higher than that of the control group at 24 hours and 48 hours.
[0041] Example 3: Effect of BDSF on the migration of endothelial cells
[0042] In this example, HUVEC was selected as the migration research object, and cell chemotaxis and scratch experiments were used to characterize the migration effect of BDSF on endothelial cells.
[0043] 1. Experiment on chemotaxis of HUVEC cells by BDSF
[0044] S1. Take HUVECs with good growth status and suspend the cells in serum-free (endothelial cell culture medium) ECM;
[0045] S2. HUVECs were seeded in the upper chamber of Transwell, with 100 μL per well containing 1×10 4 cells;
[0046] S3. Add 500 μL of serum-free ECM to the lower chamber of the Transwell, and add PBS (control group), BDSF with a final concentration of 20 μM, and VEGF at 20 ng / mL for treatment, and incubate in a cell culture incubator at 37°C, 5% CO2 for 24 h;
[0047] S4. After incubation, use a cotton swab to carefully remove excess cells from the upper chamber and place the Transwell chamber in 4% paraformaldehyde for fixation for 30 min.
[0048] S5. Stain it with 0.5% crystal violet for 15 min and wash it carefully with PBS five times;
[0049] S6. Measure the absorbance of each well at 450 nm using a microplate reader and capture the image of the stained cells using an optical microscope.
[0050] Figure 3 A-B are the results of the chemotaxis experiment of HUVEC cells by BDSF. It can be seen from the figure that compared with the control group, BDSF, like VEGF, enhances the migration ability of HUVEC cells.
[0051] 2. BDSF scratch test on HUVEC
[0052] S1. Take HUVECs with good growth status, inoculate them into 6-well plates, add ECM complete medium and incubate overnight until the cell density grows to 70%-80%;
[0053] S2. Use a sterile 1 mL pipette tip to draw a straight line vertically on the bottom of a 6-well plate, and draw three straight lines in each well;
[0054] S3. Wash the cells three times with PBS, remove the crossed cells, add 1 mL of serum-free ECM, and add PBS (control group), BDSF with a final concentration of 20 μM, and VEGF at 20 ng / mL for treatment, and incubate in a cell culture incubator at 37°C, 5% CO2 for 24 h;
[0055] S4. At three time points, 0h, 12h, and 24h, images of cell migration were captured using an optical microscope and quantitatively analyzed using ImageJ.
[0056] Figure 3 C-D are the results of BDSF-HUVEC scratch test. It can be seen from the figures that the migration rate of HUVEC cells treated with BDSF and VEGF is significantly higher than that of the control group.
[0057] Example 4: Effect of BDSF on the Tube-forming Effect of Endothelial Cells
[0058] In this example, HUVEC was selected as the angiogenesis research object to explore the effect of BDSF on HUVEC cells in vitro angiogenesis. The specific steps are as follows:
[0059] S1. Place the pipette tip and 96-well plate in a -20°C refrigerator overnight to pre-cool, and place the matrix gel in a 4°C refrigerator overnight to pre-cool;
[0060] S2. Before the experiment, place the pre-cooled matrix gel on ice water, and place the pipette tip and 96-well plate on a flat ice pack;
[0061] S3. Evenly spread the matrix gel in a 96-well plate, 50 μL per well. Be careful to avoid bubbles during each operation;
[0062] S4. Place the 96-well plate with Matrigel in a 37°C incubator and incubate for 1 h to form a gel;
[0063] S5. Take HUVECs with good growth status and inoculate them into 96-well plates covered with matrix gel. Add ECM complete medium (100 μL per well) containing 1×10 4 The cells were treated with PBS (control group), BDSF with a final concentration of 20 μM, and VEGF at 20 ng / mL, respectively, and incubated in a cell culture incubator at 37°C and 5% CO2;
[0064] S6. After 3 h and 6 h of incubation, images of angiogenesis were captured using an optical microscope and quantitatively analyzed using ImageJ.
[0065] Figure 4 This is the result of the in vitro angiogenesis test of HUVEC cells treated with BDSF. It can be seen from the figure that compared with the control group, HUVEC cells treated with BDSF and VEGF formed more capillaries, and the angiogenesis-promoting effect was time-dependent, that is, the total length of blood vessels, percentage of blood vessel area and number of vascular nodes were significantly increased in 6 hours of angiogenesis compared with 3 hours.
[0066] Example 5: Effects of Medium-chain Alkenes on HUVEC
[0067] This example studies the effects of BDSF, DSF, cis-2-medium carbon chain olefinic acid and trans-2-medium carbon chain olefinic acid on HUVEC, wherein the cis-2-medium carbon chain olefinic acid selected in this example is cis-2-dodecenoic acid (BDSF) and cis-2-decenoic acid (cis-C10), the trans-2-medium carbon chain olefinic acid selected in this example is trans-2-hexadecenoic acid (trans-C6), trans-2-octadecenoic acid (trans-C8), trans-2-decenoic acid (trans-C10) and trans-2-dodecenoic acid (trans-C12), and the medium carbon chain olefinic acid derivative selected in this example is cis-11-methyl-2-dodecenoic acid (DSF).
[0068] The treatment of HUVECs was carried out in accordance with Example 2, except that PBS, DSF with a final concentration of 20 μM, BDSF, trans-C12, cis-C10, trans-C10, trans-C8 and trans-C6 were added in step S2 for treatment.
[0069] Figure 5The figure shows the effects of DSF, BDSF, trans-C12, cis-C10, trans-C10, trans-C8 and trans-C6 on the proliferation rate of HUVEC cells. It can be seen from the figure that the proliferation effects of DSF and trans-C6 on HUVEC are significantly higher than those of the control group, while the proliferation effects of BDSF, trans-C12, cis-C10, trans-C10 and trans-C8 on HUVEC are better, all of which are more than 60% higher than those of the control group.
[0070] Example 6: Effects of medium-chain olefinic acids on nerve cells
[0071] This example studies the effects of BDSF, DSF, cis-2-medium carbon chain olefinic acid and trans-2-medium carbon chain olefinic acid on the neural cell PC12, wherein the cis-2-medium carbon chain olefinic acid selected in this example is cis-2-dodecenoic acid (BDSF) and cis-2-decenoic acid (cis-C10), the trans-2-medium carbon chain olefinic acid selected in this example is trans-2-hexadecenoic acid (trans-C6), trans-2-octadecenoic acid (trans-C8), trans-2-decenoic acid (trans-C10) and trans-2-dodecenoic acid (trans-C12), and the medium carbon chain olefinic acid derivative selected in this example is cis-11-methyl-2-dodecenoic acid (DSF); the specific steps are:
[0072] S1. Take PC12 cells with good growth status, inoculate them into 6-well plates, add RPMI-1640 complete medium and incubate overnight until the cell density grows to 70%-80%;
[0073] S2. PC12 cells were treated with DSF, BDSF, cis-2- and trans-2-meso-olefinic acid for 12 h respectively;
[0074] S3. The cell culture medium was discarded, and PC12 cells were washed three times with PBS, treated with LPS (5 μg / mL), and incubated under 1% O2 hypoxic conditions for 24 h;
[0075] S4. After co-incubation, prepare cell suspension, add Annexin V-FITC and PI to stain the cells, and incubate at 37°C in the dark for 30 min;
[0076] S5. Detect cell apoptosis using flow cytometry and analyze using FlowJo software;
[0077] S6. The survival rate of PC12 cells was detected using CCK-8 kit.
[0078] Figure 6Figure 3 shows the effects of DSF, BDSF, trans-C12, cis-C10, trans-C10, trans-C8 and trans-C6 on PC12 neural cells. It can be seen from the figure that the ratio of normal cells and apoptotic cells and the cell survival rate of PC12 cells treated with DSF and trans-C6 were significantly higher than those of the control group, while the PC12 cells treated with BDSF, trans-C12, cis-C10, trans-C10 and trans-C8 further showed a higher ratio of normal cells and apoptotic cells and cell survival rate than those of the control group, which were more than 50% higher.
[0079] The present invention provides a method for using a medium carbon chain olefinic acid and its derivatives in the preparation of drugs for promoting angiogenesis and nerve function recovery. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.
Claims
1. Application of medium-chain olefinic acids and their derivatives in the preparation of drugs for promoting angiogenesis and nerve function recovery.
2. The use according to claim 1, characterized in that: The medium-carbon olefinic acid includes cis-2-medium-carbon olefinic acid and trans-2-medium-carbon olefinic acid; the medium-carbon olefinic acid derivatives include cis-2-medium-carbon olefinic acid derivatives and trans-2-medium-carbon olefinic acid derivatives.
3. The use according to claim 2, characterized in that: The carbon chain length of the medium-chain olefinic acid and its derivatives is 6 to 16.
4. The use according to claim 3, characterized in that: The carbon chain length of the medium-chain olefinic acid and its derivatives is 6 to 12.
5. The use according to claim 2, characterized in that: The cis-2-medium carbon chain olefinic acid is cis-2-decenoic acid and / or cis-2-dodecenoic acid; the trans-2-medium carbon chain olefinic acid is any one or a combination of trans-2-hexadecenoic acid, trans-2-octadecenoic acid, trans-2-decenoic acid, and trans-2-dodecenoic acid; and the cis-2-medium carbon chain olefinic acid derivative is cis-11-methyl-2-dodecenoic acid.
6. The use according to claim 1, characterized in that: The concentration of the medium-carbon olefinic acid and its derivatives is 5 to 100 μM.
7. The use according to claim 6, characterized in that: The concentration of the medium-carbon olefinic acid and its derivatives is 10-60 μM.
8. The use according to claim 7, characterized in that: The concentration of the medium-carbon olefinic acid and its derivatives is 20-40 μM.
9. The use according to claim 1, characterized in that: The dosage form of the drug is any one of tablets, capsules, powders, oral liquids, syrups, granules, dripping pills, orodisintegrating tablets, sustained-release tablets, patches, micropills, microcapsules, liposomes, microspheres, sustained-release preparations, and controlled-release preparations.
Citation Information
Patent Citations
Trans-2-decenoic acid derivative and drug containing same
CN104254521A
Application of CDNF (cerebral dopamine neurotrophic factor) in preparation of ischemic cerebrovascular disease drugs
CN107149673A
Preparation method and applications of ganglioside derivatives containing unsaturated fatty acid chains
CN108498523A
Composition for prevention or treatment of neurodegenerative diseases comprising undecylenic acid and / or conjugated linoleic acid
KR1020120019327A
Agent having neurotrophic factor-like activity
US20100204498A1
